Clinical trialNCT06357377Not, yet, recruitingPhase 1Interventional

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

SponsorNeonc Technologies, Inc.Enrollment12Choroid Plexus Carcinoma, ChildhoodDiffuse Midline Glioma, H3 K27M-MutantHigh Grade GliomaPediatric Tumor of BrainPediatric Tumor of Brain StemPediatric Tumor of CNS+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Josh Neman, PhD
NeOnc Technologies Holdings, Inc.
Study Director
clinicaltrials.gov ↗
Thomas Chen, MD, PhD
NeOnc Technologies Holdings, Inc.
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NEO100

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2026
Primary completion: 31 Oct 2026
Completion: 31 Oct 2026
Last update posted: 14 Jan 2026
Registered enrollment: 12
Registry id: NCT06357377

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.